The University of Kentucky has prepared and tested mithramycin oxime derivatives reported to be useful for the treatment of cancer and neurological disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented tricyclic compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors and thus reported to be useful for the treatment of gram-negative bacterial infections.
Gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity have been disclosed in a Pfizer Inc. patent.
Cyrus Therapeutics Inc. has designed molecular glue degraders comprising a cereblon (CRBN)-binding moiety acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers potentially useful for the treatment of cancer.
Dice Alpha Inc. has prepared and tested substituted 6-imidazopyridazine IL-17A modulators potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
Guangdong HEC Pharmaceutical Co. Ltd. has reported compounds acting as GTPase KRAS and mutant inhibitors and thus reported to be useful for the treatment of cancer.
Work at Acelink Therapeutics Inc. has led to the identification of Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of cancer, lung, mitochondrial and sickle cell diseases, cardiovascular, inflammatory, neurological and renal disorders.
Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, Parkinson’s and Huntington’s disease, cancer, amyotrophic lateral sclerosis, stroke, mitochondrial myopathy and Charcot-Marie-Tooth disease, among others.
RSS